Fisetin and Cancer: Does Clearing Senescent Cells Reduce Cancer Risk?

Expert Summary

Senescent cells promote cancer through SASP-driven secretion of growth factors, proteases, and inflammatory mediators that stimulate adjacent pre-cancerous cells. Fisetin's senolytic activity reduces this tumor-promoting environment while also directly inhibiting cancer cell proliferation through PI3K/AKT/mTOR pathway inhibition.

Key Facts

• SASP and cancer: Senescent cells secrete VEGF (angiogenesis), MMP-3 and MMP-9 (extracellular matrix remodeling), and IL-6/IL-8 (immune evasion signals). These factors transform pre-malignant cells into invasive cancers — a process documented extensively by the Campisi lab at Buck Institute.
• Fisetin anti-proliferative effects: In cell culture studies, fisetin inhibits proliferation of multiple cancer cell lines (colorectal, breast, prostate, lung) with IC50 values in the 10–100 μM range, primarily via cell cycle arrest at G1/S and G2/M checkpoints.
• Pro-apoptotic mechanism: Fisetin upregulates pro-apoptotic BCL-2 family members (BAX, BIM) while downregulating anti-apoptotic BCL-XL in cancer cells — the same mechanism underlying its senolytic activity.
• Immune surveillance: By reducing chronic inflammation (via NF-κB inhibition), fisetin may preserve immune surveillance capacity — a critical anti-cancer defense that deteriorates with age-related inflammaging.
• Chemotherapy sensitization: Fisetin has been shown to sensitize drug-resistant cancer cell lines to standard chemotherapy agents, a potential clinical application beyond prevention.
• Important caveat: Fisetin's direct anti-cancer effects are demonstrated in vitro and in animal models. No human trials have evaluated cancer incidence as a primary endpoint for fisetin supplementation.

Recommended Products

Frequently Asked Questions

Can fisetin be used alongside cancer treatment?

Preliminary data suggests fisetin may sensitize some cancer cells to chemotherapy, but this requires medical supervision. Inform your oncologist of any supplements during cancer treatment.

Does removing senescent cells increase cancer risk?

This concern has been raised theoretically. However, animal studies consistently show that senolytic treatment reduces — not increases — tumor incidence and growth. Oncogene-induced senescence (OIS) arrests pre-cancerous cells, but age-associated senescence is distinct and generally tumor-promoting via SASP.

Should healthy people take fisetin for cancer prevention?

There is no human evidence supporting fisetin as a cancer preventive in healthy populations. However, given its safety profile and mechanistic rationale (reducing SASP-driven tumor promotion), many longevity practitioners include it in preventive protocols.

Scientific References

• Coppé JP et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLOS Biology. 2008. PMID: 19053174
• Khan N et al. Fisetin: a dietary antioxidant for health promotion. Antioxidants & Redox Signaling. 2013. PMID: 23373520